ARS Pharmaceuticals reports strong revenue growth, while higher losses weigh on shares after Q1 results.
Stock Earnings Results
May 15, 2026
Table of Contents
May 15, 2026
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported first-quarter results with revenue above expectations, but shares came under pressure after the company posted a wider-than-expected loss.
ARS Pharmaceuticals is a biopharmaceutical company focused on severe allergic reaction treatments. Its lead product, neffy, is a needle-free epinephrine nasal spray used for emergency treatment of severe allergic reactions, including anaphylaxis.
The company reported a loss of $0.61 per share, wider than estimates for a loss of $0.53, representing a negative 15.1% earnings surprise. Revenue came in at $22.68 million, above estimates of $22.35 million, with revenue growth of 184.5%.
ARS reported $17.5 million in U.S. net product sales of neffy during the quarter.
Total revenue reached $22.7 million, up sharply from $8.0 million in the prior-year period. Revenue also included $2.5 million in collaboration revenue and $2.7 million in supply revenue.
The company said more than 28,000 healthcare providers have prescribed neffy to date, with about half becoming repeat prescribers.
That matters because neffy is still building market adoption as the first needle-free epinephrine option. Repeat prescribing can signal growing physician comfort with the product.
ARS said its proposal to CVS Caremark for commercial formulary inclusion is in the final stages of approval.
The company expects a definitive update in early June, with a target effective date of July 1, 2026. Broader formulary access could improve coverage, reduce friction for patients, and support prescription growth.
The company reported a net loss of $60.6 million, compared with a net loss of $33.9 million in the prior-year quarter.
Selling, general, and administrative expenses rose to $72.2 million from $41.1 million, driven by direct-to-consumer marketing and sales force expansion. ARS increased its sales team from 106 to 148 representatives.
ARS ended the quarter with $201.0 million in cash, cash equivalents, and short-term investments.
Management said that balance is sufficient to fund operations through cash-flow break-even.
Investors are likely to watch whether ARS can turn neffy adoption into faster revenue growth while controlling commercial spending.
The key areas are:
ARS Pharmaceuticals delivered strong revenue growth, but the earnings miss shows the cost of building a new commercial market.
The neffy launch is gaining traction, but higher marketing and sales expenses are keeping losses elevated. The next major test is whether formulary access and prescriber adoption can accelerate revenue enough to justify the spending.
Platforms like LevelFields track earnings misses, layoffs, dividend increases, and leadership changes, stock reactions together, helping investors identify when healthcare stocks are moving on adoption momentum versus profitability concerns.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE